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Congenital sideroblastic anemias (CSA) are inherited diseases resulting from 
defects in heme biosynthesis, mitochondrial iron-sulfur cluster (ISC) assembly, or 
mitochondrial translation. CSAs are characterized by pathological iron deposits in the 
mitochondria of bone marrow erythroblasts. Recently the Fleming Lab at Boston 
Children’s Hospital has reported mutations in HSPA9, a chaperone involved in ISC 
assembly, as a cause of nonsyndromic CSA. Here we identified a CSA patient harboring 
two variants in HSCB, encoding a binding partner of HSPA9: a paternally inherited 
promoter variant (c-134C>A) and a maternally inherited frameshift variant (T87fs) 
predicted to result in a truncated protein. To better understand the pathophysiology of 
these variants, we investigated HSCB protein expression and function in patient-derived 
skin fibroblasts. Patient fibroblasts show evidence of decreased HSCB protein levels. 
shRNA targeting HSCB was employed to specifically suppress HSCB expression in the 
K562 erythroid-like cell line model. shRNA-infected K562 cells presented with perturbed 
iron homeostasis, a shift to glycolytic energy production, and diminished 
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hemoglobinization. Targeted deletion of murine Hscb is embryonic lethal prior day E7.0. 
Tissue-specific lox-Cre transgenic lines, including Vav-, EpoR- and Mx-Cre demonstrate 
that Hscb is essential for hematopoiesis and erythropoiesis. Mutant mice present with 
hematopoietic defects similar to the index patient. Vav-Cre animals die prior to post-natal 
day 9 with decreased red cell counts, white cell counts, and decreased hemoglobin 
compared to wild-type animals. Floxed-null EpoR-Cre animals die before embryonic day 
13. To excise Hscb specifically in the hematopoietic compartment of adult animals, 
conditional Mx-Cre animals were generated through bone marrow transplantation and 
temporally induced with polyinosinic-polycytidylic acid treatment. The animals died 22 
days post-injection with decreased red blood cells, white blood cells, hemoglobin, and an 
overall decline in hematopoiesis of the bone marrow. These data demonstrate that HSCB 
is required for erythropoiesis and hematopoiesis and that the patient mutations are a 
pathogenic cause of CSA.  
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INTRODUCTION  HSCB, A CO-CHAPERONE IN MITOCHONDRIAL IRON-
SULFUR CLUSTER BIOGENESIS, IS A NOVEL CANDIDATE GENE FOR 
CONGENITAL SIDEROBLASTIC ANEMIA 
 
Congenital sideroblastic anemias (CSA) are inherited diseases resulting from 
defects in heme biosynthesis, mitochondrial iron-sulfur cluster (ISC) assembly, or 
mitochondrial translation. CSAs are characterized by pathological iron deposits in the 
mitochondria of bone marrow erythroblasts. Recently the Fleming Lab at Boston 
Children’s Hospital has reported mutations in HSPA9, a chaperone involved in ISC 
assembly, as a cause of non-syndromic CSA. Here we identified a CSA patient harboring 
two variants in HSCB, encoding a binding partner of HSPA9: a paternally inherited 
promoter variant (c-134C>A) and a maternally inherited frameshift variant (c.259dup, 
p.Thr87Asnfs*27) predicted to result in a truncated protein. To better understand the 
pathophysiology of these variants, we investigated HSCB protein expression in patient-
derived skin fibroblasts. Patient fibroblasts show evidence of decreased HSCB protein 
levels. shRNA targeting HSCB was employed to specifically suppress HSCB expression 
in the K562 erythroid-like cell line model. shRNA-infected K562 cells presented with 
perturbed iron homeostasis, a shift to glycolytic energy production, and diminished 
hemoglobinization. Targeted deletion of murine Hscb is embryonic lethal prior day E7.0. 
Tissue-specific lox-Cre transgenic lines, including Vav-Cre, EpoR-Cre and Mx-Cre 
demonstrate that Hscb is essential for hematopoiesis and erythropoiesis. Mutant mice 
present with hematopoietic defects similar to the index patient. Floxed-null Vav-Cre 
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animals die prior to post-natal day 9 with decreased red cell counts, white cell counts, and 
compared to wild-type animals microcytic anemia. Floxed-null EpoR-Cre animals die 
before embryonic day 13. To excise Hscb specifically in the hematopoietic compartment 
of adult animals, floxd-null Mx-Cre animals were generated. Bone marrow 
transplantation was employed in adult irradiated recipients and Mx-Cre was temporally 
induced with polyinosinic-polycytidylic acid treatment. The animals died 22 days post-
injection with decreased red blood cells, white blood cells, hemoglobin content, and an 
overall decline in hematopoiesis of the bone marrow. These data demonstrate that HSCB 
is required for erythropoiesis and hematopoiesis and that the patient mutations are a 
pathogenic cause of CSA.  
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INTRODUCTION 
1. Iron is Essential for Functional Erythroblast Biology 
Iron is one of the most ubiquitous transition metals found in human biology. It is 
essential for a vast number of biological processes including DNA and protein synthesis, 
energy metabolism, and respiration (Camaschella, 2015). The ability of iron to transition 
between the ferrous (Fe2+) and ferric (Fe3+) state is crucial for its participation in redox 
reactions; however, free iron is toxic. Through Fenton chemistry, it produces intracellular 
reactive oxygen species that are damaging to lipids, proteins and DNA. Therefore, a 
careful regulation of iron homeostasis is required inside cells and the human body 
(Coffey and Ganz, 2017). The largest consumers of iron are erythroblasts, red blood cell 
(RBC) precursors that use iron to synthesize heme and hemoglobin while undergoing 
erythropoiesis, the differentiation process into mature RBCs. Iron is used by 
erythroblasts, and many other cells types, to make both heme and iron-sulfur clusters 
(ISCs). Heme and ISC are incorporated as prosthetic groups in enzymes and other 
proteins.  Iron-sensing regulatory proteins (IRPs) regulate iron transport, utilization, 
storage, and export at an intracellular level. IRPs themselves are regulated by iron levels. 
Disruptions in iron utilization or the iron regulatory systems can lead to pathological 
conditions (Muckenthaler et al., 2017).  
1.1. Hematopoiesis and Erythropoiesis 
Hematopoiesis is the process by which different blood cell lineages are generated 
through differentiation of hematopoietic stem cells (HSCs). It occurs in three distinct 
waves during mammalian development, beginning in the yolk sac, transitioning to the 
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fetal liver, and concluding with adult hematopoiesis in the bone marrow (Barminko et al., 
2016). The first primitive wave of hematopoiesis occurs in the yolk sac early in 
embryonic development and produces nucleated megaloblastic erythroblasts called 
primitive erythroblasts, as well as macrophages and platelet progenitor cells. The 
primitive erythroblasts are characterized by an ability to express embryonic globin genes 
and remain nucleated. The second wave occurs later in embryonic development within 
the yolk sac and is characterized by erytho-myeloid progenitors (EMPs), which can 
generate erythroid colonies and other myeloid lineages. EMPs migrate to the fetal liver, 
express fetal globin genes, enucleate, and produce definitive erythroblasts. The third 
wave is characterized by the production of HSCs, which migrate to the fetal liver to 
expand, and then travel to the bone marrow, the major site of adult hematopoiesis 
(Barminko et al., 2016; Nandakumar et al., 2016). In adult animals, stress erythropoiesis 
can occur in the spleen in times of anemia and hypoxia to compensate for ineffective 
steady-state erythropoiesis (Paulson et al., 2011). HSCs give rise to several lineages of 
cells in adult hematopoiesis, starting with a common multipotent cell population 
harboring CD34 cell surface markers. This population ultimately leads to the production 
of common lymphoid progenitors (CLP), granulocyte monocyte progenitors (GMP), and 
common myeloid progenitors (CMP), which give rise to megakaryocytic-erythroid 
progenitor (MEP)  (Barminko et al., 2016).  
Erythropoiesis is the terminal differentiation of MEPs into mature RBCs. This 
highly regulated process is required to produce nearly 200 billion RBCs daily to meet 
oxygen demand (Koury, Ponka, 2004). The hormone erythropoietin (EPO) is produced 
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by the kidney and promotes RBC production by binding to the EPO receptor on the 
surface of committed erythroid progenitors, promoting their survival and preventing 
apoptosis (Mariotti et al., 2013). There are two major common erythroid progenitors 
(EP): blast-forming unit erythroid (BFU-E) and colony-forming unit erythroid (CFU-E) 
cells. BFU-E is the earliest committed EP and gives rise to CFU-E progenitors. The CFU-
E differentiates into the proerythroblast, a cell with both a large cell size and nucleus, 
which is also the earliest morphologically identifiable EP (Nandakumar et al., 2016). The 
proerythroblast undergoes mitosis and differentiates sequentially into 2 basophilic, 4 
polychromatic, and 8 orthochromatic erythroblasts (Barminko et al., 2016). 
Orthochromatic erythroblasts expel their nucleus to form reticulocytes. Reticulocytes 
mature in bone marrow and blood circulation to become RBCs. The erythroblast 
maturation process involves expulsion of the mitochondria and ribosomes, leading to 
decreased overall cell size, and changes in cell surface markers (Nandakumar et al., 
2016). Cell surface markers and receptors are specific to the stage of erythropoiesis and 
are used as an identification method via flow cytometry (Wangen et al., 2014). Some of 
the most widely employed human erythroblast markers include CD71 (Transferrin 1 
receptor/TFR1), CD117 (SCF receptor), glycophorin A (GPA), Band 3, and α4-integrin 
(Nandakumar et al., 2016). During erythropoiesis, an increase in TFR1 expression leads 
to a concomitant enhancement of iron uptake. Iron uptake and heme production are 
closely regulated along with globin protein synthesis to ensure proper hemoglobin 
synthesis, an energy intensive process required by erythroblasts differentiating into 
erythrocytes (Chiabrando et al., 2014).  
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1.2. Erythroblast Iron Acquisition  
Transferrin (TF) is a serum glycoprotein containing two high-affinity ferric iron 
binding sites. It prevents iron from generating reactive oxygen species and sequesters it 
from iron-seeking pathogens. TF transports iron to tissues and binds to TFR1 (Wallace, 
2016). TFR1 is expressed on the cell surface of most cell types and is highly expressed 
by erythroblasts. Erythroblasts take up a vast majority of iron-bound transferrin for 
hemoglobin synthesis during erythropoiesis (Ganz and Nemeth, 2012; Muckenthaler et 
al., 2017). Once bound to TFR1, the iron-TF-TFR1 complex undergoes endocytosis, 
forming an intracellular endosome. Acidification of the endosome by proton pumps 
release ferric iron from TF. An endosomally-bound ferrireductase (STEAP3) reduces 
ferric to ferrous iron and divalent metal transporter 1 (DMT1/NRAMP2) shuttles ferrous 
iron out of the endosome and into the cytoplasm. The endosome containing apo-TF and 
TFR1 fuses with the cell surface, releasing TF to circulation and restoring TFR1 to the 
cell surface (Gulec et al., 2014; Camaschella et al., 2016).  
1.3. Erythroblast Iron Utilization 
Ferrous iron has several fates: utilization, storage, or export (Muckenthaler et al., 
2017). Free iron can be stored in ferritin, a 500 kDa macromolecule found in the cytosol 
that can hold upwards of 4,000 Fe atoms. Ferritin is an assemblage of 24 subunits of two 
varieties: heavy (FTH1), a ferroxidase that uses hydrogen peroxide to convert ferrous 
iron to ferric iron, and light (FTL), which generates ferric iron from hydroxyl phosphate. 
When required, ferritin molecules are degraded by lysosomes to free iron. The sole iron 
exporter, ferroportin 1 (FPN1), exports iron into the serum (Finazzi, Arosio, 2014).   
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Iron is used as a component of heme, incorporated into ISC, and is itself a 
cofactor of several enzymes. In erythroblasts, iron is mainly shuttled into mitochondria to 
produce heme and allow ISC assembly. Current research suggests ferrous iron may enter 
the mitochondria through a “kiss and run” method whereby the endosome containing iron 
makes direct contact with the mitochondria to transfer (Sheftel et al., 2007). A 
mitochondrial innermembrane transporter, mitoferrin 1 (MFRN1, SLC25A37) is highly 
expressed in erythroid precursor cells and transports iron into the mitochondrial matrix. 
ATP-binding cassette, subfamily B, member 10 (ABCB10) protein is predicted to 
stabilize MFRN1 to assist in iron trafficking.  Frataxin (FXN) is an iron chaperone 
thought to play a role in delivering iron to ISC assembly proteins. Mitochondrial iron is 
involved in heme and iron-sulfur cluster biosynthesis, both of which are critical pathways 
for a functional erythroblasts (Hentze et al., 2010).  
1.4. Heme and Hemoglobin Biosynthesis 
Heme is a prosthetic group consisting of a ferrous ion chelated to a 
protoporphyrin ring.  Heme participates in redox reactions in the oxidative 
phosphorylation complexes of the electron transport chain, and is the core component of 
hemoglobin. Iron, contained within heme, is used to bind globin chains and as an oxygen 
carrier in RBCs (Fujiwara, Harigae, 2015). Heme is synthesized in the mitochondria of 
all cells but its synthesis is regulated differently in erythroid precursors due to 
extraordinarily high levels of heme biosynthesis required for hemoglobin production. 
Heme biosynthesis begins with the condensation of one glycine molecule, transported 
into the inner mitochondrial matrix by solute carrier family 25 member 38 (SLC25A38), 
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and one succinyl CoA, generated from the citric acid cycle, to form 5-aminolevulinic acid 
(ALA) by the enzyme ALA synthase (ALAS). ALAS requires pyridoxal 5’-phosphate 
(PLP, vitamin B6) as a cofactor (Bergmann et al., 2010). There are two ALAS isoforms 
encoded by separate genes. ALAS1 encodes a non-erythroid specific form that can be 
negatively inhibited by free heme levels. Free heme, like iron, can be toxic due to 
participation in redox reactions. ALAS2, which is located on the X chromosome, encodes 
an erythroid-specific form of ALAS. ALAS2 is not inhibited by heme because 
erythroblasts require a large amount of heme production for hemoglobin biosynthesis 
when undergoing hemoglobinization and differentiation into mature RBCs (Chiabrando 
et al, 2014).  
ALA exits the mitochondria via a currently unidentified transporter, undergoes 
several enzymatic reactions to form coproporphyrinogen III, and is then transported back 
into the mitochondria. Several reactions occur in the mitochondrial matrix prior to the 
formation of protoporphyrin IX, the penultimate step in heme biosynthesis. 
Ferrochelatase (FECH), the rate-limiting enzyme, forms a complex with MFRN1 and 
ABCB10 and incorporates ferrous iron into free protoporphyrin IX to produce heme 
(Hentze et al., 2010; Chiabrando et al., 2014).  FECH is a homodimer with each 
monomer containing a [Fe2-S2] ISC in the C-terminus. It is predicted that the ISC are 
used to stabilize the protein. Loss of ability to coordinate the ISC leads to decreased 
enzyme activity and diminished heme synthesis (Schneider-Yin et al., 2000). Heme can 
be exported from the mitochondria via feline leukemia virus C receptor 1 (FLVCR1) and 
is incorporated in globins in the cytosol (Chiabrando et al., 2014). 
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Hemoglobin is a complex of 4 globin subunits produced in erythroblasts 
incorporating heme. Different globins are produced at different stages of human 
development: embryonic globin (ε), fetal globin (α-ɣ), and adult globin (α-𝛽) (Ginder, 
2015). Heme synthesis regulates the rate of hemoglobin production by interacting with 
several key proteins involved in globin synthesis; Btb And Cnc Homology 1 (BACH1) 
(Tahara et al., 2004) and heme-regulated eIF2 subunit α kinase (HRI) (Chen, 2004). Low 
levels of heme suppress globin synthesis and elevated levels of heme promote globin 
production to maintain proper ratios of heme and globins. Additionally, this prevents 
excessive globin synthesis leading to toxic intracellular conditions (Chen, 2004).  
1.5. Iron-Sulfur Cluster Assembly 
ISCs are highly reactive cofactors synthesized in the mitochondria and cytosol. 
They participate in redox reactions. ISCs are assembled in several major configurations: 
rhomboid [Fe2-S2], cuboidal [Fe3-S4], and cubane [Fe4-S4]. They are critical components 
of many biological pathways, including heme biosynthesis (FECH), the citric acid cycle 
(ACO2), DNA metabolism and repair, iron homeostasis (IRP1/ACO1), and oxidative 
phosphorylation (respiratory complexes I, II, and III) (Ye, Rouault, 2010; Alfadhel and 
Nashabat, 2017). ISC assembly is an evolutionarily conserved pathway found in bacteria, 
yeast, and mammals. Multimeric complexes are recruited which include scaffold, 
chaperone, and co-chaperone proteins required to assemble ISC and transfer them to the 
target proteins, coordinating with specific residues for proper insertion. ISC assembly 
occurs in the cytosol and mitochondria, but is better understood in the mitochondria. It 
begins with the formation of a protein complex involving a cysteine desulferase (NFS1), 
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a scaffold protein (ISCU), an iron-donating protein frataxin (FXN), and a smaller 
accessory protein called LYRM4 (also known as ISD11) (Alfadhel and Nashabat, 2017; 
Maio, Rouault, 2016). FXN is an allosteric regulator of NFS1, is thought to donate iron to 
ISC assembly, and therefore regulates the fate of iron in the mitochondria. FXN binds to 
NFS1, opening the active site, and enabling NFS1 to place a free cysteine molecule in the 
active site. Current research suggests that this step is facilitated by LYRM4 (Alfadhel and 
Nashabat, 2017). NFS1 removes sulfur from this cysteine, forming alanine. It converts 
the sulfur to form persulfide, transferring it to ISCU to form the nascent ISC. Another 
donor of iron is predicted to be a complex of glutathione and glutaredoxin (Maio and 
Rouault, 2016). Nevertheless, it is known that ferrodoxins (FDX1/2) and ferrodoxin 
reductase (FDXR) provide electrons to form the final configuration of the cluster (Maio 
and Rouault, 2015). 
Once the ISC has been assembled, it must be transferred to the target protein. 
Human heat shock cognate protein 20 (HSCB/HSC20), a highly conserved cochaperone 
protein belonging to the DnaJ family binds to ISCU, and its respective chaperone protein, 
heat shock protein 70 mitochondrial  or HSPA9, also known as mortalin. It also binds to a 
targeted ISC-recipient apo-protein (Maio, Rouault, 2015). HSCB uses three highly 
conserved hydrophobic residues in its C-terminal domain to transiently bind to ISCU 
(Uhrigshardt et al., 2010). The N-terminal J-domain of HSCB contains a histidine, 
proline, aspartate (HPD) motif that is common among the DnaJ family and is used to 
interact with and stimulate the ATPase activity of HSPA9. HSPA9 has a nucleotide-
binding domain (NBD) that binds adenosine triphosphate (ATP), as enzymatic energy 
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source, in its active state. HSCB has a leucine-tyrosine-arginine (LYR) motif as a 
recognition site to bind the recipient ISC apo-protein (Maio and Rouault, 2015). 
HSPA9 is a major participant in mitochondrial ISC assembly (Shan and 
Cortopassi, 2016) and stimulates ISC-recipient protein refolding and conformational 
changes using ATP hydrolysis (Maio and Rouault, 2016). The current model dictates 
HSCB simultaneously bind ISCU and the recipient apo-protein.  HSCB then uses the 
DnaJ-domain to interact with the NBD of HSPA9, promoting ATP hydrolysis, and brings 
ISCU in close proximity to the substrate binding domain of HSPA9. ATP hydrolysis 
causes the transfer of the ISC to the apo-protein, transfer of the nascent ISC-containing 
protein to HSPA9, and the resulting ADP is bound to the NBD. This hydrolysis also 
induces a conformational change in HSPA9 that releases HSCB and ISCU (Shan and 
Cortopassi, 2016; Rouault and Maio, 2017). A nucleotide exchange factor (NEF) binds to 
ADP-bound HSPA9 that promotes the release of the nascent ISC protein and the 
exchange of ADP for ATP, returning HSPA9 to is active state (Rouault and Maio, 2017). 
Glutaredoxin 5 (GLRX5) is an alternative iron-sulfur cluster acceptor, similar to 
HSPA9 that can transfer ISC to apo-proteins using additional targeting proteins (Lill et 
al., 2012). ATP binding cassette, subfamily B, member 7 (ABCB7), is predicted to 
transport sulfur compounds from the mitochondria to the cytosol to be incorporated used 
in cytosolic iron-sulfur cluster assembly (CIA) (Berndt, Lillig, 2017). CIA is performed 
by separate protein assemblage as compared to ISC assembly in the mitochondria. 
Additionally, ISC generated by CIA can also be assembled to proteins found in the 
nucleus (Netz et al., 2014).  
  12 
1.6. Intracellular Iron Regulation by the IRE-IRP System 
Iron regulatory proteins 1 and 2 (IRP1 and IRP2) maintain cellular iron 
homeostasis by binding a short conserved stem-loop of the 5’ or 3’ untranslated regions 
(UTR) of specific mRNA. These elements, called iron responsive elements (IREs), are 
found in key iron related mRNA (Pantopoulos, 2004). These include genes for iron 
uptake (TFR1, DMT1), iron storage (FTH, FTL), iron “utilization” (ALAS2), and iron 
export (FPN1). There are also IREs in genes not directly related to iron metabolism, 
including mitochondrial aconitase (m-ACO/ACO2), an enzyme in the citric acid cycle, 
hypoxia-induced transcription factor-2α (HIF-2α), a transcription factor responsible for 
EPO production in the kidney, and several other genes, suggesting IRPs interact with 
pathways other than iron metabolism (Anderson et al., 2012). Low iron levels will result 
in IRP1/2 binding the 5’UTR IREs to repress translation, and binding to the 3’UTR IREs 
to promote mRNA stabilization and translation. Normal or high iron levels result in 
decreased IRP binding to IREs, resulting in translational activation of iron utilization 
genes and decreased mRNA stabilization of iron import genes to avoid iron overload 
(Pantopoulos, 2004; Muckenthaler et al., 2008). 
IRP1 and IRP2 share approximately 64% genetic identity. They are both 
expressed in all cell types. They both bind IREs with high-affinity, but have distinct 
characteristics. IRP1 is a cytosolic bi-functional protein that is converted from the IRP 
mRNA-binding apoprotein form to an isoform of the enzyme aconitase (c-ACO/ACO1) 
when acquiring an ISC (Anderson et al., 2012). This switch is dependent upon 
intracellular iron status. Positive iron status promotes ISC assembly, ISC incorporation 
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into IRP1 and its transition to ACO1, decreasing the ability for IRP1 to act as an agent to 
bind IREs (Rouault, Maio, 2017). Despite IRP2 sharing the same residues used to bind 
ISCs, it is not known to bind any ISC. IRP2 exhibits no aconitase activity. IRP2 is 
predominantly expressed in erythroblasts and binds IREs in states of low intracellular 
iron. IRP2 is rapidly ubiquitinated and degraded when iron or heme levels are high 
(Anderson et al., 2012). Analysis of IRP levels can be used to elucidate if there are 
problems within iron homeostasis or iron-sulfur cluster assembly (Muckenthaler et al., 
2008; Ye, Rouault, 2010). 
1.7. Murine Models of Human Disease 
 Murine models are used to study various aspects of biology that are difficult to 
study in humans. Foundational research on hematopoiesis and erythropoiesis has been 
completed in mice due to the similarities in their erythroid biology and genetics. They are 
useful models for human diseases (Nandakumar et al., 2016). However, there are notable 
differences in cell surface markers found in murine and human blood cell linages. Murine 
erythroblasts contain markers that are not present on human erythroblasts during different 
stages of erythropoiesis. These include CD44 (cell adhesion molecule, marker of early 
erythroblast) and Ter119 (a marker of late-stage erythroblasts (Jing et al., 2015)).  
 A major advancement in murine systems is the use of a recombinase (Cre) to 
excise genetic material flanked by lox (flox) recognition sites, called the lox-Cre system 
(Sauer, 1998). Tissue-specific recombinases are used to target gene knockout in specific 
tissues or cell lines at different developmental time points. Some recombinases are 
inducible. Vav-Cre is a constitutively expressed recombinase that targets hematopoietic 
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and endothelial cell lineages (Siegemund et al., 2015). EpoR-Cre is a constitutively 
expressed recombinase in the erythroid lineage that becomes active at embryonic days 
E8.5-10.5 (Heinrich et al, 2004). Mx-Cre is a widely-expressed inducible recombinase 
activated using polyinosinic-polycytidylic acid (Gudmundsson et al., 2014).  
2. Sideroblastic Anemia  
Sideroblastic anemia is a rare form of anemia characterized by pathological 
deposits of iron in mitochondria of bone marrow erythroblasts. Prussian blue-positive 
granules are seen in the perinuclear mitochondria of stained bone marrow aspirates, 
forming a ring around the nucleus, also called a ring(ed) sideroblast (Bottomley and 
Fleming, 2014). There are two forms of sideroblastic anemia: acquired sideroblastic 
anemia, and the genetically inherited form, called congenital sideroblastic anemia 
(CSA).  The most common form of acquired sideroblastic anemia is refractory anemia 
with ringed sideroblasts (RARS). RARS belongs to the family of myelodysplastic 
syndrome (MDS), a clonal bone marrow disorder characterized by decreased RBCs 
(anemia), decreased white blood cells (leukopenia) and platelets (thrombocytopenia) as 
well as a predisposition to acute myeloid leukemia. Somatic mutations in the gene 
encoding the splicing factor SF3B1, a core component of the RNA splicing complex, are 
found in most patients with RARS (Cazzola, Malcovati, 2015).  
Most causes of CSA are associated with defects in heme biosynthesis, ISC 
assembly, or mitochondrial translation. Research in CSA has led to a more thorough 
understanding of the biology of iron use and transport inside the cell (Bergmann et al., 
2010). There are two general classes of CSA, non-syndromic and syndromic. Non-
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syndromic CSAs are usually caused by defects in the heme biosynthesis and ISC 
assembly pathways. Syndromic CSA are associated with abnormalities in organ systems 
other than the blood and blood-forming organ. Most of the causes of syndromic CSA 
involved defects in mitochondrial translation defects of nuclear encoded genes 
(Bottomley and Fleming, 2014). 
2.1. Pathophysiology of CSA 
 Individuals are diagnosed with CSA based on the presence of ringed sideroblasts 
in bone marrow aspirates as identified by Prussian blue staining. The size and 
morphology of the RBCs is a clue for further classification. Microcytic RBCs are cells 
with a decrease mean cell volume (MCV) whereas normocytic or macrocytic are RBCs 
with a normal and elevated MCV respectively. CSAs associated with heme synthesis 
defects generally present with a decreased MCV and mild-to-severe anemia. Known 
causes of non-syndromic CSA include mutations in ALAS2, SLC25A38, GLRX5, and 
HSPA9, which can present with decreased or normal MCV (Bottomley and Fleming, 
2014). The most prevalent and well-studied form of CSA is X-linked sideroblastic 
anemia (XLSA) and is due to mutations in the ALAS2 gene. This anemia is marked as 
microcytic and hypochromic, and may respond to pyrodoxine supplementation owing to 
the requirement of the enzyme for this vitamin (Cazzola and Malcovati, 2015). 
Autosomally inherited mutations in the gene for SLC25A38, the mitochondrial glycine 
transporter, lead to a decreased ability to synthesize heme. The primary treatment option 
for these individuals is chronic blood transfusions with iron chelation therapy (Fleming, 
2011). Mutations in GLRX5, an ISC assembly protein, have been shown to severely 
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impact erythroblasts, leading to an increase in iron intracellularly and decreased ISC-
proteins; however, some patients with GLRX5 mutations have been reported without 
CSA (Stehling and Lill, 2013. 
Syndromic CSA tend to have earlier onset in childhood, variable MCV, and more 
severe anemia. Known causes of syndromic CSA include mutations in ABCB7, a 
transporter implicated in ISC assembly, mutations in PUS1/YARS2, genes involved in 
mitochondrial tRNA synthesis, mutations in SLC19A2, a thiamine transporter, and 
variable mitochondrial genome deletions (Bottomley and Fleming, 2014). Deletions or 
mutations in the mitochondrial genome can impact genes that encode subunits of the 
mitochondrial respiratory complex chain, as in Pearson-Marrow Pancreas Syndrome 
(PMPS). Mutations some of the enzymes required to synthesize functional mitochondrial 
tRNA molecules, such as pseudouridine synthase 1 or mitochondrial tyrosyl-tRNA 
synthetase 2 lead to myopathy, lactic acidosis, and sideroblastic anemia (MLASA). 
Mutations in SLC19A2 cause thiamine-responsive megaloblastic anemia (TRMA) that is 
associated with non-type I diabetes and sensorineural deafness (Fleming, 2011). 
Mutations in ABCB7, the mitochondrial ISC exporter involved in cytosolic ISC 
assembly, lead to X-linked sideroblastic anemia with cerebellar ataxia (Bergmann et al., 
2010). 
 
2.2. Recent Developments in CSA 
Nearly all causes of CSA have been identified as defects in pathways relating to 
heme biosynthesis, mitochondrial protein translation, and ISC assembly (Fleming, 2011). 
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However, there are additional causes of CSA that have yet to be identified. The Fleming 
laboratory is using exome sequencing as a platform to identify new CSA gene candidates.  
For example, this approach yielded NDUFB11, a core component of complex I in 
the mitochondrial respiratory chain as a CSA candidate gene. Functional studies 
confirmed that mutations in NDUFB11 result in a novel form of X-linked congenital 
sideroblastic anemia (Lichtenstein et al., 2016).  
Additionally, the Fleming lab identified TRNT1 as a CSA candidate gene. TRNT1 
encodes the enzyme responsible for nuclear and mitochondrial tRNA maturation. 
Supported by functional studies and gene knockdown using siRNA, mutations in TRNT1 
were confirmed as a cause for CSA (Chakraborty et al., 2014).  
Candidate gene approached using Sanger sequencing identified HSPA9 as a 
candidate due to its role in ISC assembly. Functional studies in yeast were completed to 
better understand the mechanism of disease found in the CSA individuals. This 
confirmed that a single severe mutation in conjunction with a common single nucleotide 
polymorphism led to a dramatic decrease in HSPA9 production. HSPA9 is thus a 
causative gene of non-syndromic CSA (Schmitz-Abe et al., 2015).  
Goals of Thesis 
 A female proband with an unequivocally syndromic CSA was identified by 
exome sequencing with 2 previously unreported variants in HSCB, the co-chaperone for 
HSPA9 and ISCU. One allele is a maternally-inherited frameshift (c.259dup, 
p.Thr87Asnfs*27), predicted to form a truncated protein.  The other is a paternally-
inherited variant in the promoter of HSCB (c-134C>A). The initial goal of this study was 
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to validate HSCB as the gene responsible for CSA in this patient, and to determine the 
impact of these variants in patient-derived skin fibroblasts on iron homeostasis and 
proteins utilizing iron and ISCs. cDNA complementation of HSCB in patient fibroblasts 
was an essential initial step established. Additionally, we sought to suppress HSCB 
expression in the erythroid-like cell line model K562 to determine the loss of HSCB has 
an effect on hemoglobinization, iron homeostasis, energy metabolism, and viability. 
Finally, we utilized a conditional murine model to knockout HSCB in specific tissues 
using the Cre-lox system to determine if sideroblastic anemia can be recapitulated in 
mice. As HSCB defects have been reported to affect IRP binding, an additional goal of 
this study was to determine if IRP1 or IRP2 knockout mice could be bred with HSCB 
knockout mice to rescue the phenotype. 
Principal Objective 
The principal objective of this study is to use patient-derived skin fibroblasts, 
erythroid-like cell lines, and murine models to confirm if HSCB is a critical component 
in iron-sulfur cluster biogenesis, is required for erythropoiesis, and if HSCB is a novel 
causative gene of congenital sideroblastic anemia. 
 
 
 
 
 
 
  19 
MATERIALS AND METHODS 
Sample Acquisition & DNA Sequencing 
The Genetic Basis of Microcytosis and Iron Disorders (GBMID) study at Boston 
Children’s Hospital enrolled individuals GBMID-356 (proband, referred as 356), 
GBMID-357 (referred as 357), GBMID-358 (referred as 358), and GBMID-359 (referred 
as 359) (Figure 1A). Samples obtained with the patient’s consent included peripheral 
blood for DNA sequencing. The Fleming Lab at Boston Children’s Hospital performed 
exome sequencing on these individuals and identified variants in HSCB. Sanger 
sequencing was employed to confirm the variants in HSCB. A skin fibroblast cell line 
was generated from proband 356, and normal discarded skin from surgical procedures 
was obtained from the pathology cutting room at Boston Children’s Hospital to establish 
human control skin fibroblasts (HCSFB). This enabled establishment of control cell lines 
HCSFB-3 (H3), HCSFB-5 (H5), and HCSFB-6 (H6).  
Establishment of Primary Cell Lines and Cell Culture 
Primary skin fibroblast cultures were derived from skin biopsies. Five samples of 
tissue, approximately 1 mm2 in size, were placed in a 6-well tissue culture plate in 1 mL 
of Dulbecco’s Modified Eagle’s Medium (DMEM, Gibco) supplemented with 10% fetal 
bovine serum (FBS, Sigma), 1% penicillin-streptomycin (P/S, Gibco) and 1% glutamine 
(gln, Gibco), hereafter referred to as DMEM-Complete (DMEM-C). The tissues were 
covered with a glass cover slip and an additional 2 mL DMEM-C were added. The cells 
were incubated at 37°C with 5% CO2 and 95% humidity. The cells were passaged at 85% 
confluency using 0.25% Trypsin (Gibco) per manufacturer’s protocols, washed in PBS 
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1X, resuspended in 10 mL DMEM-C, and seeded into a T75 culture flask. All fibroblast 
lines were grown in T75 supplemented with 10 mL DMEM-C until 85% confluency. 
They were passaged, frozen, and continued to grow until passage five. All experiments 
were performed on fibroblasts grown after passage five. For confluency experiment, cells 
were grown to different concentrations prio before harvesting. Untreated cell lines were 
pelleted for multiple uses: immunoblotting, mitochondrial isolation, and enzyme activity 
assays. All samples were stored at -80°C until use. 
 K562 is a chronic myelogenous leukemia (CML) cell line with erythroid-like 
properties obtained from ATCC. The cells were grown in T25 and T75 tissue culture 
flasks with Roswell Park Memorial Institute (RPMI Media 1640, Gibco) culture media 
supplemented with 10% FBS, 1% P/S, and 1% gln, hereafter referred to as RPMI-
Complete (RPMI-C). Cells were passaged at 1x106 cells/mL. They were grown at similar 
incubator conditions as the fibroblasts. K562 were infected with shRNA directed against 
HSCB (see below), treated with sodium butyrate for hemoglobinization experiments, and 
used to determine cell energy phenotype profiling by Seahorse. 
Fibroblast Mitochondrial Isolation 
 Mitochondria were isolated from fibroblasts by the Mitochondrial Isolation Kit 
for Cultured Cells (abcam, ab110170) according to the manufacturer’s instructions. 
Mitochondria were resuspended in Laemmli 1X (4% SDS-based, 20% glycerol, 10% 
dithiothreitol, 0.004% bromophenol blue, and 0.125 M Tris HCL, pH of 6.8) for SDS-
PAGE analysis. 
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Protein Quantification 
 Proteins resuspended in protein solublization buffer (Laemmli 1X for 
immunoblotting, extraction buffer for enzyme activity) were quantified using a detergent 
compatible colorimetric assay from Bio-Rad (cat#5000111). Proteins were quantified 
according to manufacturer’s instructions using the Bio-Rad SmartSpec 3000 per 
manufacturer’s instructions. Proteins analyzed for citrate synthase and complex IV 
activity were solubilized in extraction buffer per the manufacturer’s recommendations. 
Measurement of Citrate Synthase and Complex IV Activity 
 Dry fibroblast pellets were resuspended in extraction buffer (Citrate Synthase 
Activity Assay Kit, abcam, ab119692). Protein concentrations were determined and 
measurement of citrate synthase activity was performed (N=3, 1.5 µg) according to the 
manufacturer’s protocol. Measurement of complex IV activity (N=3, 25 µg) was 
performed using a Complex IV Human Enzyme Activity Microplate Assay Kit (abcam, 
ab109909) according to manufacturer’s instructions. 
HSCB Vector and Empty Vector Generation 
 Human HSCB cDNA ORF was obtained cloned into the pCMV6-Entry vector 
from OriGene (#RC200843). TOP10 electrocompetent E. coli cells (Thermo-Fisher, 
C404010) were transformed and positively transformed bacteria were selected for on an 
LB agar plate supplemented with kanamycin (50 µg/ml). Bacterial colonies were grown 
overnight at 37°C in 5 ml LB with kanamycin. Cultures were PCR screened with 
OriGene-supplied primers (XL39, VP1.5) to confirm the presence of the unaltered 
HSCB-containing plasmid. Bacteria containing the vector were subcloned into 500 mL 
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LB supplemented with kanamycin and grown overnight at 37°C. Plasmid was isolated 
using a PureLink HiPure Plasmid Filter Maxiprep Kit (Invitrogen, #K210017) per 
manufacturer’s instructions. An empty vector (Ø) was generated using enzymes EcoRI-
HF (NEB, R3101T) and EcoRV-HF (NEB, R3195T) to excise the HSCB cDNA from the 
Pcmv6-Entry backbone by incubating at 37°C for 1 hour followed by heat inactivation at 
65°C for 20 minutes. Cut ends were blunted by T4 DNA polymerase (NEB, M0203) 
according to manufacturer’s protocol. T7 DNA Ligase (NEB, M0318S) was used to 
ligate the cut ends together following manufacturer’s protocol. Excision of HSCB cDNA 
ORF was confirmed using OriGene-provided primers. The empty vector was then 
propagated by previously described methods.  
Fibroblast Complementation using PEI Transfection 
 Fibroblasts were plated at 0.3x106 cells per 10-cm culture plate in DMEM-C 24 
hours prior to transfection. On the day of transfection, cells were changed into fresh 
DMEM-C and 14.5 µg of plasmid was combined with 870 uL of fresh DMEM and 
homogenized. 28.9 µL of polyethylenimine (PEI, Sigma, 2 µg/µL) was added to the 
plasmid-DMEM solution, homogenized, and incubated at room temperature for 5 minutes 
at room temperature. The 900 µL plasmid-DMEM-PEI was added dropwise to each plate 
to distribute the mixture evenly. Media was again changed after 24-hours. 72-hours post-
transfection, the media was aspirated; cells were washed with PBS, and removed from 
the plate through trypsinization. Cell pellets were then resuspended in Laemmli 1X buffer 
and homogenized for SDS-PAGE analysis. 
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Infection of K562 Cells with shSCR or shHSCB 
 Lentivirus particles targeting SCR or HSCB were purchased from Sigma. 
Scramble (SCR) shRNA (Sigma, SHC002V) was used as a negative control. The shSCR 
encoded control hairpin is designed to demonstrate positive infection conferred by 
puromycin resistance, but does not target any specific protein. Several constructs 
encoding shRNA directed against HSCB were tested in a pilot assay, and two constructs, 
TRCN0000138234 (sh34) and TRCN00008487 (sh87) proved the most efficient at 
decreasing HSCB expression after puromycin selection. It was established that 2.4x107 
TU/ml was required for optimal efficiency.  
 0.1x106 K562 cells were seeded in 500 µL of media per well in a 48-well tissue 
culture plate. Lentivirus or a “non-infected” (NI) control, was added (either shSCR, sh34, 
or sh87) and cells were homogenized. After 24 hours, cells were diluted with 500 µl 
RPMI-C and transferred to a 12-well tissue culture plate. After an additional 48 hours, 
cells were washed three times with PBS-1X to remove any remaining virus; they were 
resuspended in fresh media and transferred to a 6-well tissue culture plate or T25 flask 
depending on confluency. Puromycin (1 µg/mL) was added to select for shRNA infected 
cells. 
 At days 6 and 10 post-infection, cells were counted, washed and pelleted. Cells 
were resuspended in Laemmli 1X. Cell surface TFR1 expression was determined by flow 
cytometry using a CD71 antibody conjugated to FITC (Miltenvi). 0.03x106 cells were 
washed in PBS-1X supplemented with 2% FBS, named FACS buffer, and stained with 
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CD71-FITC for 20 minutes at 4°C. Unstained cells were used as control to measure 
endogenous fluorescence. Following incubation, cells were washed with FACS buffer to 
remove unbound CD71-FITC and fluorescence was determined using the BDverse 
cytometer and results are represented using BDverse software. 
Sodium Butyrate Treatment of K562 Cells 
 shRNA-infected or non-infected (NI) K562 cells were treated with 6.0 mM 
sodium butyrate (SB) for 96 hours to promote differentiation. Cell lines without SB 
treatment were grown in parallel as non-hemoglobinized control. After 96 hours, cells 
were counted, washed, and pelleted. Cell pellets were resuspended in Laemmli 1X for 
immunoblotting. TFR1 expression at the cell surface was determined as previously 
described. 
Determination of Metabolism Phenotype using Seahorse XFe 96 Analyzer 
 Baseline and stress energy phenotype of NI and shRNA-infected K562 cells (20 
days post-infection with shRNA) was determined using Cell Energy Phenotype Test Kit 
(Seahorse, 103325-100) on a Seahorse XFe 96 extracellular flux analyzer. Cell lines were 
loaded onto a Cell-Tak (Corning, 1206D69) pretreated 96-well cell culture microplate on 
the day of assay following manufacturer’s instructions. An optimal cell density of 
7.5x104 cells per well, FCCP concentration of 0.25 µM, and oligomycin concentration of 
1.0 µM was determined empirically. A single injection of FCCP and oligomycin has been 
employed to effectively disrupt the proton gradient of the mitochondria and ATP 
synthase of the mitochondrial respiratory complex respectively.  
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Immunoblotting 
 SDS-PAGE analysis was compelted on 15 µg of protein resuspended in reducing 
Laemmli 1X buffer (dithiothreitol, 50 µM final) and denatured for 5 minutes at 90°C. 
Bromophenol blue (BPB) dye was added prior to sample loading. Samples were 
subjected to electrophoresis through 4-20% TruPAGE precast polyacrylamide gels 
(Sigma, PCG2012).  Blots were run in Tris-Tricine buffer (1X) for 10 minutes at 100 V, 
and then an additional 70 minutes at 150 V to complete separation. Blots were transferred 
to nitrocellulose membranes for 90 minutes at 85 V in transfer buffer (100 mM glycine, 
17 mM Tris Base, 20% ethanol). Ponceau staining was employed to confirm complete 
transfer and assess protein loading. Membranes were cut using the loaded ladder as guide 
and were blocked for 90 minutes in Tris Buffered Saline (TBS) supplemented with 0.1% 
tween-20 (TBS-T) and 5% milk. All primary antibodies were incubated overnight in 5% 
milk with TBS-T. Membranes were washed in TBS-T for 30 minutes and blots were 
incubated with either anti-mouse or anti-rabbit secondary antibody conjugated with 
horseradish peroxidase (1:10,000) in 5% milk with TBS-T for 90 minutes and washed in 
TBS-T for 30 minutes. To reveal the proteins by chemiluminescence, ECL Prime and 
ECL Select (Amersham) were used per the manufacturer’s instructions. Proteins were 
visualized on a ChemiDoc MP and densitometry analysis was completed using Image 
Lab (version 4.1). After immunoblot analysis, blots were washed in TBS-T, blocked for 
30 minutes in TBS-T with 5% milk and hybridized to other primary antibodies, or were 
stored at -20°C. 
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Generation of Hscb Mice 
 Knockout and conditional Hscb mice were generated prior to the start of this 
thesis work. Heterzoygous null Hscb animals (Hscb+/-, C57Bl/6J, N=10) and Hscb 
conditional (Hscb+/C, C57Bl/6J, N=12) were previously established in the Fleming Lab. 
Previous work had determined that Hscb null (Hscb-/-) animals die before embryonic day 
7.0. 
 Hscb+/- animals were bred individually to the hematopoietic-specific Vav-Cre 
(Tg(Vav1-cre)1Graf), the erythroid-specific EpoR-Cre (Eportm1(EGFP/cre)Uk), and 
temporally inducible Mx-Cre animals to generate Hscb+/- Vav-Cre+, Hscb+/- EpoR-Cre+, 
and Hscb+/- Mx-Cre+ (Tg(Mx1-cre)1Cgn) animals. Hscb+/C animals were interbred to 
generate double-floxed (double-conditional) animals (HscbC/C). HscbC/C were bred with 
Hscb+/- Vav-Cre+, Hscb+/- EpoR-Cre+, and Hscb+/- Mx-Cre+ animals to generate 
experimental animals. Target experimental animals for Vav-Cre are the genotypes 
HscbC/+ Vav-Cre+, HscbC/+ Vav-Cre-, HscbC/- Vav-Cre+, and HscbC/- Vav-Cre-. The 
breeding scheme for EpoR-Cre was to generate animals that were HscbC/-  EpoR-Cre+ to 
provide high certainty that EpoR-Cre was deleting in the erythroid compartment. The 
breeding scheme for Mx-Cre was to generate HscbC/- Mx-Cre+ animals that could then be 
paired with HscbC/C animals to generate HscbC/- Mx-Cre+ and HscbC/- Mx-Cre- embryos 
to be used for bone marrow transplantation. All mouse genotypes were determined using 
the Transnetyx automated genotyping platform. 
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 All mice were housed in the animal facility at Boston Children’s Hospital 
following a standard diet and care conditions as approved by the Institutional Animal 
Care and Use Committee (IACUC). Animals used for breeding or in experiment were at 
least 6 weeks of age. Adult mice were humanely euthanized by CO2 asphyxiation and all 
young animals (before day 7) were euthanized by decapitation. Necropsy was performed 
by applying ethanol (70%) to the stomach of euthanized animals to mat the fur, the 
abdominal cavity was opened, and relevant tissues were harvested. To harvest embryonic 
tissue, pregnant females were euthanized on days 10.5 or 14.5 of pregnancy, the uterine 
horn was excised, opened, and individual gestational sacs were separated and observed. 
Embryos were excised from the gestational sac for further analyses. Embryos were 
placed in a 10-cm tissue culture plate and were washed with PBS-1X three times. 
Bone Marrow Transplant 
 A timed mating was performed by pairing a C57B6/J N11 HscbC/- Mx-Cre+ male 
with HscbC/C female at 8 weeks of age. The female was timed to 14.5 days of pregnancy 
and was humanely euthanized. The embryos were extracted from the animal. Limbs were 
used for genotyping of the embryos. One fetal liver of an HscbC/- Mx-Cre+ embryo and 
one fetal liver of an HscbC/- Mx-Cre- embryo were gently disaggregated in 1 mL DMEM 
with 1% P/S, and filtered using a 70 µm cell strainer. The fetal liver cell suspension was 
diluted to 5x106 cells/mL. Ten bone marrow recipient-wild-type C57Bl/6J females at 6 
weeks of age received 1050 Rads from a Cs57 irradiation source, divided into two doses 
separated by three hours. 1x106 fetal liver cells in 200 µL of DMEM with 1% P/S were 
injected retro-orbitally into each recipient animal. This established five HscbC/- Mx-Cre+ 
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recipients and five HSCB-/C Mx-Cre- recipients. The animals were carefully monitored 
for 8 weeks to permit the fetal liver stem cells to engraft in the bone marrow. They were 
provided autoclaved food in a sterile environment with water at pH 2.5 supplemented 
with sulfamethoxazole to avoid infection during the engraftment process.  
 After 8 weeks, the animals underwent induction of Mx-Cre with poly-inosine-
poly-cytosine (pIpC). Each animal received a 300 µg of pIpC on alternate days for five 
days, totaling three injections. Retro-orbital blood was collected for CBCs at days 0, 7, 
14, and 22. Tail nicks were performed to generate blood smears on days 4, 5, 6, 8, 10, 
and 12 to monitor for the presence of siderocytes in circulation. The animals were 
euthanized at day 22 to preclude suffering. Liver, kidney, spleen, thymus, duodenum, 
heart, and lung were harvested post-euthanasia for histology. Cytospins were prepared 
(slides per animal with 0.2x106 cells/slide) to observe the morphology of cells in the 
spleen and bone marrow. Tissues, including kidney, spleen, liver, and blood serum, were 
harvested for iron analysis. Tissues, including thymus, spleen, bone marrow, and whole 
blood, were harvested for immunoblot analysis. Bone marrow cells were flushed and 
isolated for DNA analysis. 
 Cells derived from bone marrow and spleen tissues were analyzed to determine 
erythroblast populations by flow cytometry, using the antibodies CD44 conjugated to 
APC and Ter119 conjugated to FITC. Cells were processed using the same protocol as 
described for K562 cell line flow cytometry. Erythroblast populations were determined 
by gating for Ter119+, cell size and CD44 staining as reported (Liu et al., 2013). 
Remaining bone marrow samples were washed in FACS buffer. RBCs were lysed using 
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RBC lysis buffer from Qiagen for 5 minutes at room temperature. Cells were washed and 
stained for 30 min at 4°C with Mouse Lineage Antibody Cocktail conjugated with APC 
(BD), Ly-6A/E (Sca-1) Monoclonal Antibody conjugated with PE-Cy7 (eBioscience) and 
CD117 (c-Kit) Monoclonal Antibody conjugated with PE (Bioscience). The LSK strategy 
staining was used to determine the number of hematopoietic stem cells (Lineage- Sca-1+ 
and CD117+).  
Complete Blood Counts 
 Complete blood counts (CBCs) were performed on 7-day old Hscb Vav-Cre pups. 
Blood was obtained from neck bleeds using 37.5 µL of blood resuspended in 262.5 µL of 
PBS, at a 1:8 dilution. CBCs were also performed on the Hscb Mx-Cre bone marrow 
transplant animals. Blood was obtained from retro-orbital (RO) bleeds totaling 75 µL of 
blood resuspended in 225 µL of PBS, at a 1:4 dilution. All CBCs were performed on an 
Advia 120 Hematology Analyzer. 
Statistical Analysis 
 All statistical analysis and graphical representation were performed using Graph 
Pad Prism (version 7.03). Statistically significant was considered a p-value <.05. 
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  RESULTS 
Decreased Expression of HSCB in Patient-Derived Skin Fibroblasts 
 The purpose of the GBIMD study is to identify new genes responsible for CSA 
and other iron metabolism disorders. Most individuals with the diagnosis of CSA have 
previously been sequenced for ALAS2 or other common CSA genes prior to enrollment. 
The patient and the patient's family were previously referred to Dr. Fleming after the 
CSA diagnosis of the proband and were consented according to protocol. Blood samples 
were obtained from the proband (356), and unaffacted members of the family: father 
(357), mother (358), and brother (359).  Hematological data of the family are summarized 
in Table 1. The proband 356 presents with microcytic anemia. Platelets and white blood 
cell (WBC) counts are abnormal in the patient; furthermore, the father, mother, and 
brother also have slightly abnormal CBC values. 
 
Red blood cell (RBC), mean cell volume (MCV), hemoglobin (HGB), white blood cell 
(WBC) and platelet (PLT) analysis of the family harboring HSCB variants.  
Exome sequencing demonstrated that this family harbors variants in HSCB and no other 
candidate CSA gene. The maternal frameshift variant (c.259dup, p.Thr87Asnfs*27) is 
Table 1: Hematological Parameters of HSCB Family from Complete Blood Counts
Proband 356 5.36 77.6 14.7 2.87 89
Father 357 4.65 101.1 15.5 6.48 227
Mother 358 4.04 96.8 13.2 5.53 338
Brother 359 4.83 91.9 14.9 3.53 260
3.75-5.07 83.5-90.2 11.4-15.1 5.78-10.33 146-326
3.75-4.45 82.7-89.4 10.9-13.4 5.82-9.32 174-333
PLT             
(cells x 103 /uL)
Normal Ranges
Male
Female
 RBC                 
(cells x 106 /uL)
MCV       
(fl)
HGB        
(g/dL)ID
WBC          
(cells x 103 /uL)
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inherited by the son (359) and the proband (356). However, the paternal promoter variant 
(c-134C>A) is inherited only by the proband (Figure 1B). Bone marrow aspirates 
showed ringed sideroblasts, diagnostic of the disease (Figure 1C). HSCB is a co-
chaperone for HSPA9, and mutations in HSPA9 lead to CSA. Here it is hypothesized that 
both variants found in 356 cause decreased HSCB protein expression, leading to a defect 
in ISC assembly, resulting in sideroblastic anemia.  
 To confirm that these variants impact HSCB protein levels, an immunoblot of 
patient fibroblast was performed for HSC70 (cytosolic control), HSPA9 (mitochondrial 
control), and HSCB (Figure 1D). H3 and H5 are unrelated control fibroblast lines. 
Previous work by the Rouault laboratory demonstrated that a defect in HSCB production 
does not affect HSPA9 expression (Maio et al., 2017). Here we not only confirmed this 
observation, but also noted a dramatic decrease in HSCB protein levels compared to both 
cytosolic and mitochondrial controls. HSCB levels are 83% lower in 356 compared to H3 
and H5, confirming our hypothesis that HSCB expression is disrupted in the proband. 
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 (A) Pedigree of the family. HSCB variants are indicated for each family member. (B) 
Sanger sequencing of HSCB exon 2. Arrow indicates site of frameshift in 356, 358, and 
359. (C) Prussian blue-staining of 356 bone marrow reveals ring sideroblasts. (D) 
Immunoblotting of HSCB protein in patient-derived skin fibroblasts for 356 compared to 
two controls (H3, H5). For HSCB, a short (top) and long (bottom) exposure are shown.  
Preparatory Studies of Mitochondrial Function and HSCB Complementation in 
Primary Skin Fibroblasts 
 Because of the decrease in HSCB protein, we hypothesized that there would be 
decreased function and or steady state levels of ISC proteins, including respiratory 
complexes, ACO2 and FECH, and decreased lipolyation of mitochondrial protein. Work 
from the Rouault laboratory in HSCB gene-targeted cell lines showed similar deficits as 
well as an increase in the mitochondrial “iron” importer MFRN2. 
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It is possible that cell confluency might impact mitochondrial mass and iron regulatory 
protein expression. As a result, to optimize the experiment, we extracted total protein 
from two control lines (H5 and H6) and confirmed that fibroblast confluency impacts 
expression of key mitochondrial proteins (Figure 2A). As confluency increases, there is a 
reciprocal decrease in mitochondria and mitochondrial complexes, citrate synthase, and 
mitofilin. Interestingly, an increase in IRP1 expression is observed as confluency 
increases. These results lead us to standardize all experiments at a confluency of 80%.  
 To ascertain if changes in HSCB expression influence mitochondrial function, complex 
IV activity assay was determined on the proband and H6 at 80% confluency. After 
normalizing complex IV activity to citrate synthase activity (Figure 2B), we observed 
that the proband’s cell line has decreased relative complex IV activity compared to a 
healthy wild-type control (paired t-test, p<0.05). Complex IV does not contain an ISC 
and should not be affected by differential HSCB expression. Altogether these results 
indicate difference in mitochondrial mass between patient-derived primary cell lines.  
Many mitochondrial functional assays require the use of isolated mitochondria. To this 
end, mitochondria were isolated from patient and control fibroblasts (Figure 2C) and 
immunoblot analysis suggested that the mitochondria remained predominantly intact 
during our isolation; however, we noted the cytosolic proteins actin and IRP1 in the 
mitochondrial extract, suggesting minimal contamination of cytosolic proteins. 
Subsequently, this protocol will be optimized to improve mitochondrial integrity and all 
further studies will be performed on purified fibroblast mitochondria. 
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Functional complementation studies in mutant cell lines can substantially contribute to 
proving causation for a candidate disease gene. We have clearly demonstrated that the 
proband has decreased HSCB expression, but have not shown that this defect is primary. 
In order to initiate this, we transfected primary fibroblasts with HSCB cDNA tagged with 
myc-DDK and were able to detect protein expression. The epitope tag is expected to 
increase the size of the overexpressed protein by approximately 12 kDa and transfected 
cells show increased HSCB levels of the appropriate size. We note two bands in HSCB 
protein immunoblot: the top band is hypothesized to be cytosolic HSCB prior to 
mitochondrial import and the bottom band mature mitochondrial HSCB. Future studies 
will determine if an increase in HSCB expression ameliorates a phenotype observed in 
the primary patient fibroblasts. 
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(A) Immunoblot analysis of multiple proteins in wild-type control cell lines H5 and H6 
harvested between 25-75% confluency. (B) Respiratory complex IV activity of 25ug total 
cell protein was measured and normalized to citrate synthase (CS) activity in proband 
and H6 cell lines. (C) Citrate synthase, HSPA9, Mitofilin, actin, IRP1 and IRP2 protein 
expression was analyzed in the mitochondrial extract (MITO) and cytosolic supernatant 
(SN) of 356 and H6. (D) Immunoblot analysis of HSC70 and HSCB in fibroblast lines 
transfected with empty (Ø) or an HSCB expression vector. (1): the expected band of 
transfected HSCB plasmid with myc-DDK and (2): endogenous HSCB. 
 
Targeted HSCB knockdown by shRNA in K562 cells leads to disrupted iron 
homeostasis, defects in hemoglobinization, and diminished mitochondrial 
respiration 
All currently published work on cell phenotypes in which HSCB expression is decreased 
has been done in non-erythroid cells; however, the proband has anemia, a disorder 
affecting erythroid cells, which have unique properties. Therefore, to more closely model 
this aspect of the disease, we employed the erythroid-like cell line K562 to ascertain the 
effect of diminished HSCB expression on hemoglobinization. Cells infected with short 
hairpine RNAs (sh4 and sh87) directed against HSCB showed diminished HSCB protein 
levels at day 6 and day 10 compared to controls (NI and shSCR) (Figure 3A). Both IRP1 
and IRP2 levels were decreased following HSCB knock down. In adition, defects in 
respiratory complex formation and protein lipolyation were observed (data not shown). 
Compared to controls, sh34 and sh87 failed to visually hemoglobinize. Uninduced, sh34 
and sh87 treated cells had decreased HbF expression and decreased IRP1/2 expression, 
which is maintained after SB induction. As red blood cell precursors differentiate, they 
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typically induce the transferrin receptor (TFRC or TFR1) in order to assimilate more iron 
required for hemoglobin production. Flow cytometry was used to measure cell surface 
TFR1 expression on SB-treated cells. NI and shSCR cell lines show an increase in TFR1 
expression in response to SB treatment, whereas sh34 and sh87 minimally increase their 
TFR1 expression after SB induction (Figure 3C), further supporting a defect in 
differentiation induced by the loss of HSCB 
HSCB is involved in ISC assembly. Respiratory complexes I-III all harbor ISC. To 
determine if HSCB knockdown impacts mitochondrial respiratory or glycolytic function, 
a Seahorse extracelluar flux analyzer was used to measure oxygen consumption 
(respiration) and extracellular acidification (glycolysis) in both control cells (NI and 
shSCR) and  sh34 and sh87 treated cell lines to determine if the energy consumption 
phenotype was altered by the deletion of HSCB. The NI and shSCR exhibited a more 
aerobic (respiration) baseline phenotype compared to sh34 and sh87, which both had a 
glycolytic baseline phenotype (Figure 3D). After treatment with FCCP and oligomycin 
to disrupt normal mitochondrial function, NI and shSCR responded to become more 
energetic, increasing their mitochondrial respiration and glycolytic pathways. sh34 and 
sh87 minimally increased their glycolytic pathways and were largely unable to perform 
additional mitochondrial respiration. This confirms that HSCB is required for proper 
mitochondrial respiratory complex function. 
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(A) Immunoblot on non-infected (NI), shSCR (Scr), sh34 (34), and sh87 (87) at days 6 
and 10 post-infection with puromycin treatment (+) or not (-); probed for HSC70, HSCB, 
IRP1, and IRP2.  (B) Immunoblot of untreated cells (UT, 96hr) or sodium butyrate 
treated cells (SB, 96hr) probing for actin, HSCB, fetal hemoglobin (HBF), IRP1, and 
IRP2 (C) Untreated cells (UT, 96hr) or sodium butyrate treated cells (SB, 96hr) assessed 
for expression of cell surface TFR1by FACS (D) Assessment of the energy phenotype of 
control, shSCR, sh34, and sh87cell lines using the Cell Energy Phenotype Test Kit. 
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Analysis of the Hematopoietic-specific Deletion of Murine Hscb  
To determine if HSCB is required for hematopoiesis, Hscb was conditionally ablated by 
breeding a conditional Hscb allele (HscbC) to a Cre expressed under the control of the 
hematopoietic-specific Vav1 promoter (Vav-Cre). HscbC/- Vav-Cre+ animals are born at 
the expected Mendelian frequency and show no physical abnormalities until post-natal 
day 5, when they begin to become progressively paler. By post-natal day 7, the HscbC/- 
Vav-Cre+ animals are overtly pale, indicating anemia, and are significantly smaller than 
their HscbC/- Vav-Cre- littermates (Figure 4A). As these animals die soon thereafter, 
post-natal day 7, we elected to humanely kill the animals at this time for a complete 
analysis. Complete blood count (CBC) analysis demonstrated a decreased of red blood 
cell count (one-way ANOVA, p<0.0001), hemoglobin concentration (one-way ANOVA, 
p<0.0001), white blood cell count (one-way ANOVA, p<0.0001), and platelet count 
(one-way ANOVA, p<0.0001) in HscbC/- Vav-Cre+ animals compared to controls; 
conversely, HscbC/- Vav-Cre- have no discernable hematological phenotype, suggesting 
that HSCB is required for hematopoiesis, and that a single, unaltered copy of Hscb is 
sufficient for survival and efficient hematopoiesis.  
  39 
 
(A) HscbC/- Vav-Cre+ are significantly more pale and are growth-retarded as compared 
to HscbC/- Vav-Cre- littermates at post-natal day 7 (top) and post-natal day 9 (bottom). 
(B) Complete blood count data representing total red blood cell count, hemoglobin, white 
blood cell count, and platelet count. HscbC/- Vav-Cre+ animals produce almost no red 
cells, white cells or platelets and generate vanishingly small amounts of hemoglobin.  
 
Analysis of the Erythroid Compartment-specific Deletion of murine Hscb 
Loss of Hscb in all hematopoietic cells causes pancytopenia, and death by post-natal day 
10. To determine if ablation of Hscb specifically in the erythroid compartment is also 
incompatible with life, a Cre placed under the control of the endogenous Epo receptor 
(EpoR-Cre) was bred to the conditional Hscb mouse model. EpoR-Cre deletes early in 
embryonic development and peak expression occurs during definitive erythropoiesis at 
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day E10.5. No live born of HscbC/- EpoR-Cre+ animals were observed. To determine 
when these animals die, timed matings were employed At day E10.5, showed HscbC/- 
EpoR-Cre- embryos have signs of definitive erythropoiesis, including a red liver and 
proper vasculature, and appear fully viable (Figure 5A). However, embryo dissection at 
embryonic day E13.5 indicated HscbC/- EpoR-Cre+ animals are dead (Figure 5B). The 
embryos are pale and less fully developed than HscbC/- EpoR-Cre- animals, but have eye 
pigmentation which starts at E12.5. This suggests the embryos died between E12.5 and 
E13.5. Future research will determine the time death in the HscbC/- EpoR-Cre+ animals 
and characterize the effect of deletion specifically on erythropiesis. Taken together, this 
model demonstrates that HSCB is essential for the transition to definitive erythropoiesis 
and production of functional erythroid cell lineages. 
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 (A) Photograph of embryonic day E10.5 HscbC/- EpoR-Cre- embryos removed from the 
gestational sac. (B) HscbC/- EpoR-Cre-(left) and HscbC/- EpoR-Cre+ (right) embryos 
were extracted from the uterine horn at E13.5 and are shown inside the gestational sac 
(top) and outside the sac (bottom). Mutant embryos are pale, indicating anemia, and 
growth retarded compared to control littermates.  
Analysis of Temporally Induced Hscb Deletion in Transplanted Mx-Cre Adult 
Animals 
Due to the early death of animals lacking Hscb in either the total hematopoietic, or more 
specifically, the erythroid compartment, we generated a model system where Hscb could 
be deleted in heamtopoietic cells of adult animals. Cre under the control of the Mx1 
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promoter can be induced after treatment with interferon-alpha or –beta or poly-inosinic-
poly-cytidylic acid (pIpC). HscbC/- Mx-Cre+ or HscbC/- Mx-Cre- fetal liver donor cells 
were transplanted into lethally irradiated recipients and Mx-Cre was induced after 8 
weeks of engraftment by injection with pIpC. Blood was collected from recipients on the 
day of induction (baseline) and days 7, 14, and 22 post-induction. Transplanted animals 
were humanely killed at day 22 post-inducted due to greatly decreased body weight and 
overt lethargy.  HscbC/- Mx-Cre+ animals weighed less than than HscbC/- Mx-Cre- 
animals at the day of euthanasia (paired t-test, p<0.05). Animals in both groups, HscbC/- 
Mx-Cre+ and HscbC/- Mx-Cre-, showed a decline in all analyzed CBC parameters at the 
first retro-orbital blood collection on post-induction day 7. This suggests that all 
responded to the pIpC injection. The HscbC/- Mx-Cre- animals quickly rebounded and 
returned to their baseline hematological parameters at day 14; conversely, hematological 
parameters in HscbC/- Mx-Cre-+ animals continue to decrease dramatically until death 
(Figure 6A). These data suggest that hematopoietic progenitors lacking Hscb in adult 
animals were unable to mature into functional red and white blood cells. 
To determine if erythroid and hematopoietic progenitor cells are present in these animals, 
bone marrow was harvested. Disaggregated cells were incubated with TER119-FITC 
antibody and CD44-APC antibodies and stained cell populations were analyzed by flow 
cytometer (Figure 6B). The Mx-Cre negative bone marrow showed normal erythroid 
maturation pattern. On the contrary, Mx-Cre positive animals showed decreased 
populations in both Ter119 and CD44 positive cells. This suggests that the Mx-Cre+ 
animals, which do not express Hscb in the erythroid compartment, are not able to 
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generate functional erythroid precursor cells. Production of earlier hematopoietic 
precursors was assessed using an LSK staining strategy for flow cytometry (Figure 6C). 
The Mx-Cre- animals show a small population of LIN (lineage)-negative-CD117-
positive-SCA-positive cells, as expected in an animal with a functional hematopoietic 
compartment. However, the Mx-Cre+ animal had a much higher population of LIN-
negative-CD117-positive-SCA-positive cells. This indicates that these animals are able to 
generate hematopoietic stem cells, but they are unable to differentiate into distinct 
lineages. Therefore, HSCB is required for effective hematopoiesis.  
 
(A) Physical and hematological parameters of transplanted animals. Body mass and 
tissue weight as assessed by percentage of body weight were measured at euthanasia. 
Hematological parameters, including red blood cell count, hemoglobin concentration, 
white blood cell count, and platelet count, were measured at day 0, day 7, day 14, and 
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day 22 post-induction of Mx-Cre. (B) Analysis of bone marrow composition by flow 
cytometry. Ter119 and CD44 staining of Mx-Cre- (top) and Mx-Cre+ (bottom) animals 
demonstrate a lack of maturing erythroid cells. (C) Bone marrow progenitor cell analysis 
by flow cytometry. Hematopoietic compartment progenitors were assessed using the LSK 
staining strategy to identify hematopoietic stem cells (LIN-negative-CD117-positive-
SCA-positive populations) in bone marrow of Mx-Cre- (left) and Mx-Cre+ (right). Mx-
Cre+ animals have increased numbers of hematopoietic stem cells. 
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DISCUSSION 
 Here we have begun to evaluate genetically and functionally the candidacy of 
HSCB as the causative gene in a single patient with congenital sideroblastic anemia. The 
proband presented with abnormal hematological parameters and ringed sideroblasts in her 
bone marrow aspirates. Exome analysis of the family pedigree identified HSCB as a 
strong potential candidate gene. Sanger sequencing confirmed that the patient harbors 
two variants in HSCB that are predicted to produce decreased HSCB protein expression; 
one, a promoter mutation, the other a frameshift coding mutation. Reduced protein 
expression was observed in patient-derived fibroblasts. While patient-derived skin 
fibroblasts are excellent source material and offer insight into the biology of an 
individual, primary cell lines have proven to be a difficult model for diseases that 
primarily affect highly specialized cell types.  
 Consequently, to further investigate the role of HSCB in ISC assembly and 
hematopoiesis, we transitioned to the erythroid-like K562 cell line to more closely study 
the relevant biology. shRNA targeted to HSCB in K562 cells demonstrated efficacy in 
decreasing HSCB protein expression with concomitant decrease in IRP1/2 levels. 
Decreased expression of IRP1/2 will impact the cell’s ability to respond to iron, including 
defects in ability to synthesize heme for hemoglobin synthesis, and iron import. A 
differentiation experiment has demonstrated that shHSCB cells have a marked decrease 
in the ability to hemoglobinize and have an increased basal cell surface TFR1 expression. 
It is hypothesized that HSCB levels may impact how the IRP system regulates or senses 
iron levels intracellularly. The IRE-IRP system is known to regulate expression of TFR1; 
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however, with an unexpected decrease in IRP1/2 levels there is an increase in cell surface 
TFR1 expression. It is possible that this alteration in TFR1 expression is a result of an 
alternate transcriptional activation mechanism. 
 Loss of HSCB is expected to decrease ISC assembly and therefore proteins that 
require ISC to function properly. This was confirmed by determining the energy 
phenotype of the shHSCB cells compared to control cell lines. Loss of HSCB promotes 
the use glycolysis for energy production, due to an inability to produce functional 
mitochondrial complexes. To further study the pathophysiology of the proband, work is 
currently underway to use CRISPR/Cas9 to target the promoter mutation in K562 cells, 
which has been determined to disrupt the binding of hematopoietic-specific transcription 
factor called ETS1.   
 Murine models have provided insight into the deletion of Hscb in different 
compartments at various time points. Deletion of HSCB in all hematopoietic cells leads 
to anemia, leukopenia, thrombocytopenia, and a failure to thrive. Deletion of HSCB in 
the erythroid compartment is embryonic lethal before E13.5 and it is predicted to be 
lethal at embryonic day E12. This is indicated by stunted development in HscbC/- EpoR-
Cre+ animals compared to EpoR-Cre- animals. Additionally, there is virtually no visible 
hemoglobinization in the embryo, indicating that the animal failed to populate the fetal 
liver with functional erythroblasts. It is predicted the EpoR-Cre+ animals die much 
sooner than the Vac-Cre+ animals due to the developmental time point EpoR-Cre 
activates. Temporal knockout of Hscb in adult animals using Mx-Cre eliminated HSCB 
expression in all engrafted hematopoietic stem cells and resulted in extreme morbidity 
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due to pancytopenia. Taken together, these data indicate that HSCB is required for 
effective hematopoiesis in mice, and whose loss will ultimately lead to death. It is 
important to demonstrate if the phenotype of the Hscb-/- animal can be rescued. A current 
strategy is to pair the Hscb+/- mouse line with Irp1-/- and Irp2-/- animals to determine if 
loss of the regulatory proteins improves erythropoiesis and hematopoiesis. Preliminary 
data indicates that Hscb+/- Irp2-/- animals may survive until embryonic day E10.5. 
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CONCLUSION 
 HSCB is a critical component of ISC assembly whose loss results in iron 
homeostasis defects, decreased mitochondrial respiration, and diminished ability to 
synthesize hemoglobin. Murine models demonstrate that loss of HSCB greatly decreases 
hematopoiesis, causes a block in erythroid maturation, and is incompatible with life. The 
two variants in HSCB harbored by the proband leads to a dramatic decrease in HSCB 
protein expression; however, the patient retains a residual amount of functional HSCB 
expression. Presumably this minimal amount is sufficient to support life. While we have 
not yet fully demonstrated that HSCB mutations lead to our index patient’s sideroblastic 
anemia phenotype, all data garnered thus far are supportive of this hypothesis. 
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